Additional file 2 of PARP inhibitor exerts an anti-tumor effect via LMO2 and synergizes with cisplatin in natural killer/T cell lymphoma

Additional file 2: Table S1. Primers for quantitative real-time PCR. Table S2. Information of antibodies applied in immunohistochemistry, immunofluorescence, co-immunoprecipitation, and western blotting. Table S3. The correlation between LMO2 expression and clinicopathologic features of 67 patients with NKTCL

Additional file 3: of The proto-oncogene Mer tyrosine kinase is a novel therapeutic target in mantle cell lymphoma

Figure S1. MerTK knockdown mediated by shMerTK 4 suppressed downstream signaling pathways and proliferation in MCL cells. Figure S2. MerTK inhibition by either shRNA or treatment with UNC2250 suppressed migration of MCL cells. Figure S3. The effects of UNC2250 on proliferation and apoptosis of MCL cells. Figure S4. Representative flow cytometry profiles for apoptosis assays in Z-138, Mino and JVM-2 cells. Figure S5. Representative flow cytometry profiles for cell cycle analysis in Z-138, Mino and JVM-2 cells. Figure S6. Proliferation of Z-138 and Mino cells was inhibited with increasing concentrations of vincristine or doxorubicin. Figure S7. Expression of microRNA-126, microRNA-335 and Gas6 in MCL cells. (DOCX 15 kb

Additional file 4 of PARP inhibitor exerts an anti-tumor effect via LMO2 and synergizes with cisplatin in natural killer/T cell lymphoma

Additional file 4: Table S4-S8. Images of original western blots. Fig. S5. Images of shNC and sh53BP1 cells

Additional file 3 of PARP inhibitor exerts an anti-tumor effect via LMO2 and synergizes with cisplatin in natural killer/T cell lymphoma

Additional file 3: Fig. S1. The CCK-8 assays for human normal NK cellstreated with different concentrations of PARPi were determined to evaluate the toxicity in vitro. Fig. S2. Fluzoparib inhibits NKTCL cell growth in vivo. Fig. S3. The hematoxylin-eosin staining for organs of mice treated with fluzoparib or not was determined to evaluate the toxicity of fluzoparib in vivo. Fig. S4. Representative imagesby immunohistochemistry of NKTCL tissues

Additional file 2: of The proto-oncogene Mer tyrosine kinase is a novel therapeutic target in mantle cell lymphoma

Supplementary Methods: Confocal immunofluorescence assays; RNA extraction, reverse transcription and Real-Time PCR. (DOCX 2252 kb

Additional file 1 of PARP inhibitor exerts an anti-tumor effect via LMO2 and synergizes with cisplatin in natural killer/T cell lymphoma

Additional file 1. Brief procedures of mRNA-sequencing analysis

Additional file 1: of The proto-oncogene Mer tyrosine kinase is a novel therapeutic target in mantle cell lymphoma

Table S1. Baseline characteristics of MCL patients receiving R-CHOP like regimens and their correlations with MerTK. Table S2. Information of antibodies applied in immunohistochemistry and western blot assays. Table S3. Combination index values of UNC2250 and Vincristine or Doxorubicin in Z-138 and Mino cells. (DOCX 28 kb